{"id":"NCT02766777","sponsor":"Sucampo Pharma Americas, LLC","briefTitle":"Evaluation of the Safety of Lubiprostone in Pediatric Participants Aged ≥ 6 Years to < 18 Years With Functional Constipation","officialTitle":"A Multicenter, 6-month, Open-label Safety Study of Lubiprostone in Pediatric Subjects Aged ≥ 6 Years to < 18 Years With Functional Constipation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-04-12","primaryCompletion":"2016-11-04","completion":"2016-11-04","firstPosted":"2016-05-10","resultsPosted":"2020-05-15","lastUpdate":"2020-05-15"},"enrollment":87,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Constipation - Functional"],"interventions":[{"type":"DRUG","name":"Lubiprostone","otherNames":["Amitiza"]}],"arms":[{"label":"Lubiprostone","type":"EXPERIMENTAL"}],"summary":"A study of the safety of lubiprostone in pediatric participants aged ≥ 6 Years to \\< 18 years diagnosed with functional constipation.","primaryOutcome":{"measure":"Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE)","timeFrame":"within 25 weeks","effectByArm":[{"arm":"Lubiprostone","deltaMin":47,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":13,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":87},"commonTop":["Diarrhoea","Vomiting","Nausea","Blood iron decreased"]}}